Prevention of Recurrent Preterm Delivery by a Natural Progesterone Agent - Full Text View

Prevention of Recurrent Preterm Delivery by a Natural Progesterone Agent

This study has been withdrawn prior to recruitment.
( Study withdrawn for financial problems. We didnwt get a grant we needed for purchesing the medication for the study. )

Sponsored by:	The Baruch Padeh Medical Center, Poriya
Information provided by:	The Baruch Padeh Medical Center, Poriya
ClinicalTrials.gov Identifier:	NCT00329316

Purpose

To examine the preterm delivery rate of a preterm delivery high risk group of pregnant women, using once daily natural progesterone agent.

Condition	Intervention
Pregnancy Premature Birth	Drug: Crinone Gel 8%

ChemIDplus related topics:

Progesterone

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Randomized, Open Label, Uncontrolled, Parallel Assignment, Efficacy Study

Eligibility

Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Pregnancy 24 weeks' gestation Preterm labor in previous pregnancies

Exclusion Criteria:

No medications for PTL or any kind of progesterone.
Cervical suture
Multiple pregnancy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00329316

Sponsors and Collaborators

The Baruch Padeh Medical Center, Poriya

Investigators


Study Chair:	Yuri Perlitz, MD	The Baruch Padeh Medical Center, Poriya

Principal Investigator:	Mosheh Ben Ami, Prof.	Head of Obs/Gyn ,The Baruch Padeh Medical center, Poriya

More Information

Study ID Numbers:	PTL Progesterone Perlitz.CTIL
First Received:	May 23, 2006
Last Updated:	June 26, 2008
ClinicalTrials.gov Identifier:	NCT00329316
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration